IRRAS Announces Regulatory Approval of IRRAflow[ ]in Australia
Stockholm, March 11, 2022 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that it received the initial regulatory approvals for its flagship product, IRRAflow, from the Australian Department of Health and Therapeutic Goods Administration (TGA) for commercial distribution in Australia. As a result of this approval, IRRAS is now listed on the Australian Register of Therapeutic Goods (ARTG), allowing the company to expand its global commercialization and begin to market IRRAflow to Australian